February 2016: SMC decisions
The Scottish Medicines Consortium has approved the following medicines for use in NHS Scotland for specific indications: fulvestrant (Faslodex; AstraZeneca); golimumab (Simponi; Merck Sharp and Dohme); guanfacine (Intuniv; Shire); panobinostat (Farydak; Novartis); and ulipristal acetate (Esmya; Gedeon Richter).
Eculizumab (Soliris; Alexion), pixantrone (Pixuvri; CTI Life Sciences) and teduglutide (Revestive; NPS Pharma) have not been recommended for use.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200782
Recommended from Pharmaceutical Press
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00Buy now